FindImmune

Executive Summary

FindImmune is a French immuno-oncology biotech company, spun off from Gustave Roussy Cancer Campus in 2018, focused on developing anticancer therapies that convert 'cold' tumors to 'hot' tumors via immune stimulation. The company leverages a proprietary platform to identify novel macrophage immune checkpoint modulators, aiming to enhance vaccination effects and antitumor immunity. Though still at an early stage with no disclosed pipeline specifics, FindImmune's approach targets the tumor microenvironment, a key area in immunotherapy. The company is privately held and based in Paris. Given its early stage, execution risk is high, but the novelty of targeting macrophage checkpoints could differentiate it in the competitive IO landscape.

Upcoming Catalysts (preview)

• Q2 2026Preclinical data presentation at major conference (e.g., AACR or ESMO)60% success
• Q4 2026Series A or seed funding round announcement40% success
• Q3 2027IND filing for lead macrophage checkpoint modulator candidate30% success